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Abstract 
Purpose: To synthesize Mannich base imidazole derivatives, and evaluate their antimicrobial, 
nematicidal and larvicidal properties . 
Methods: Compounds 1a-g and 2a-g were prepared using a Mannich condensation method. The 
chemical structures of compounds 2a-g were confirmed by Fourier transform infrared spectroscopy (IR), 
proton nuclear magnetic resonance (1H-NMR), carbon nuclear magnetic resonance (13C-NMR), and 
mass spectrometry (MS) and elemental analyses. Compounds 1a-f and 2a-f were screened for 
antimicrobial properties using an agar diffusion method. The nematicidal activity of the compounds was 
evaluated against juvenile Meloidogyne javanica as test organism  while larvicidal activity was assessed 
against the urban mosquito,  Culex. Quinquefasciatus, using a standard bioassay protocol.  
Results: Compounds 1b, 1g, 2e and 2g were highly active against a few bacterial organisms compared 
with the reference antibacterial, ciprofloxacin while the antifungal activity of compound 2d was high 
compared with the reference, clotrimazole. Compounds 1c, 1e, 1g, and 2e showed high toxicity levels of 
larvicidal activity based their half maximal lethal dose (LD50) values. Compounds 1d, 1e, 1f, 1g, 2d and 
2e were highly toxic to nematodes. 
Conclusion: Compounds 1b, 1g, 2e and 2g may be useful as lead molecules for the development of 
new classes of larvicidal, nematicidal and antimicrobial agents.  
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Culex is an important genus of mosquito that 
acts as a vector for several serious diseases, 
including filariasis, west Nile virus, dangue fever, 
yellow fever, chikungunya and other diseases 
caused by encephalitides. Nematodes are tiny 
worms, some of which are plant parasites. It is 
thought that nematode infections play an 
important role in the predisposition of a host plant 
to invasion by secondary pathogens. Edible 
plants attacked by nematodes show retarded 
growth and development, resulting in loss of 
quality and quantity of the harvest.  
 
Currently employed nematicides are slated for 
tighter regulations and less use due to 
environmental problems and human and animal 
health concerns. The optimum methods of 
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controlling mosquito larvae and nematodes 
involve the use of insecticides such as various 
organophosphates, and natural and synthetic 
heterocyclic products. New environmentally safe 
and biodegradable insecticides that specifically 
target mosquitoes and nematodes are urgently 
needed. 
 
Naturally occurring and synthetic imidazole 
derivatives are an important class of 
heterocycles that are known to exhibit various 
biological activities [1]. The imidazole nucleus is 
a major component in a variety of drugs, 
including angiotensin II receptor antagonists, 
anti-inflammatory agents, protein kinase 
inhibitors, and fungicides [2]. Imidazole also 
plays important roles in biochemical processes 
[3]. Many substituted imidazoles are used as 
fungicides and herbicides, plant growth 
regulators and therapeutic agents [4]. Imidazole 
is common compounds of a large number of 
biologically and medicinally significant 
substances [5,6], including anticonvulsant [7] and 
monoamine oxidase (MAO) inhibitors [8]. 
 
The Mannich reaction is commonly employed to 
develop agricultural chemicals such as plant 
growth regulators [9] and is an important tool in 
the synthesis and modification of biologically 
active compounds [10]. It provides a convenient 
access to many useful synthetic building blocks 
because amino groups can be easily converted 
into a variety of other functionalities [11]. 
Mannich bases often exhibit significant biological 
properties including antimicrobial [12], cytotoxic 
[13] and anticancer [14].  
 
The present investigation focuses on a   series of 
imidazole compound in a single molecular 
framework and examines their larvicidal, 






All the melting points were recorded in open 
capillary tubes and are uncorrected.  IR spectra 
were recorded in KBr on a FT–IR Shimadzu 
8201pc and ¹H NMR spectra were recorded on a 
Brucker DRX-300 MHZ. Elemental analysis (C, H 
and N) were undertaken using an Elementer 
analyzer model vario EL III. The purity of the 
compounds was checked by thin layer 
chromatography (TLC) with silica gel plates. 
 
General procedure for the synthesis of 2-[1H-
imidazol-1-yl (phenyl) methyl] hydrazinecarbo 
thioamide (1a)  
 
Imidazole (0.1 mol), thiosemicarbazide 
hydrochloride (0.1 mol), and benzaldehyde (0.1 
mol) were added in ethanol solvent (20 mL). The 
reaction mixture was refluxed 5h with 
temperature 60 oC. Then the mixture was poured 
over crushed ice. The precipitate was obtained in 
few min. then the precipitate was collected by 
filtration. The precipitate was dried and 
recrystallized from suitable alcohols. The above 
procedure was followed by all the remaining 
compounds 1a-1g. 
 
2-[1H-imidazol-1-yl (phenyl) methyl] 
hydrazinecarboxamide (2a) 
 
Imidazole, (0.1 mol), semicarbazide hydro-
chloride (0.1 mol) and benzaldehyde (0.1 mol) 
were added in   ethanol solvent (20 mL). The 
reaction mixture was refluxed 5 h with 60 oC. 
Then the mixture was poured over crushed ice. 
The precipitate was obtained in few min. then the 
precipitate was collected by filtration.
 
 
    Scheme 1: Synthetic route of compounds 1a-1g and 2a-2g 
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The precipitate was dried and recrystallized from 
suitable alcohols. The above procedure was 
followed by all the remaining compounds 2a-2g. 
 
In vitro antibacterial screening 
 
Compounds 1a-1g and 2a-2g were evaluated for 
their in vitro antibacterial activity against 
Staphylococcus aureus (ATCC-25923), 
Escherichia coli (ATCC-25922), Enterococcus 
feacalis, Pseudomonas aeruginosa (ATCC-
27853), Klebsiella pneumoniae (recultured) by 
agar diffusion method [15,16] was performed 
using Mueller–Hinton agar (Hi-Media) medium.  
 
Each compound was tested at a concentration of 
100 μg/mL in DMSO. Ciprofloxacin was used as 
the standard. The zone of inhibition was 
measured after 24 h incubation at 37 ºC (Table 
2). The minimum inhibitory concentration (MIC) 
was considered to be the lowest concentration 
that completely inhibited growth on agar plates. 
 
In vitro antifungal screening 
 
Compounds 1a-1g and 2a-2g were evaluated for 
their in vitro antifungal activity Aspergillus niger, 
Candia albicans, Aspergillus fumigatus, 
Cryptococcus neoformans and Microsporum 
audouinii (recultured) using an agar diffusion 
method [17,18] with Sabouraud’s dextrose agar 
(Hi-Media). Each compound was tested at a 
concentration of 100 μg/mL in DMSO. 
Clotrimazole was used as the standard. The 
zone of inhibition was measured incubated at 37 
°C for 24 h and MICs were determined. 
 
Evaluation of larvicidal activity  
 
The assessment of larvicidal activity of 
synthesized test compounds 1a-1g and 2a-2g 
was tested against the urban mosquitoes Culex. 
Quinquefasciatus using standard bioassay 
protocol [19]. Egg rafts of mosquito were 
obtained from a drainage system. The eggs were 
reared under standard insectary conditions at 
ambient temperature (29 ± 3 °C) and relative 
humidity (80 ± 5 %), 12:12 light: dark photoperiod 
and fed with ground shrimp feed daily.  
 
Larval development was monitored for 7 days. 
The second and third stage larvae were collected 
at the tip of a pasture pipette and placed in 
cotton bud to remove excess water and 
transferred gently to the test vial (10/vial) by 
tapping. The larval mortality was observed using 
various concentrations of synthesized 
compounds (10, 20, 30, and 40 µg/mL). 
Assessment of nematicidal activity  
 
For the determination of nematicidal activity, 
juveniles of Meloidogyne javanica were used as 
test organism [19]. Assay system was prepared 
with 2 ml Milli Q water containing different 
concentrations (10, 20, 30 and 40 µg/mL) of 
synthesized test compounds 1-6 in glass tubes.  
 
Ten juveniles of M. javanica were transferred in 
test, positive (with 2 % methanol) and negative 
(without vehicle) control tubes. Mortality was 
observed under a zoom stereomicroscope after 




The mean of the results was calculated based on 
at least 3 independent evaluations and the 
standard deviations (SD) were also calculated 
using Microsoft Excel. All LD50 values were 
calculated from the corresponding sigmoidal 
dose–response curve according to best fit 
shapes based on at least five reaction points 
using the Microsoft Office Excel 2007 software 






2-[1H-Imidazol-1-yl (phenyl) methyl] 
hydrazinecarbothioamide (1a) 
 
IR(KBr,cm-1): 3292.26(NH2), 2916.17(NH), 
1436.87(C=S), 811.98(Ar-H); 460(CH) 1HNMR 
(DMSO-d6, 300MHz): 9.53(s, 2H, NH2), 7.83(s, 
1H, CH), 7.26-7.65(m, 5H, Phenyl),  6.77(s, 1H, 
Imidazole-CH), 6.84(s, 1H, CH), 2.2(1H, NH), 
2.0(s, 1H, NH) 13C NMR (DMSO-d6, 300MHz); 
182.7 (C=S), 128.7, 126.6, 128.1, 132.5 (Pheny), 
128.6 (Imidazole ring CH=CH), 137.8 (HC=N), 
75.3 (CH). EI-MS, m/z (Relative intensity %): 
[247.28+, 42 %]. 
 
2-((4-Chlorophenyl) (1H-imidazol-1-yl) methyl) 
hydrazinecarbothioamide (1b)  
 
IR(KBr,cm-1): 3291.44(NH2), 2912.34(NH), 
1440.88(C=S), 837(C-Cl), 819.18(Ar-H), 
456(CH); 1H NMR (DMSO-d6, 300MHz): 9.43(s, 
2H, NH2), 7.62(s, 1H, CH), 7.36 - 7.16(tt, 4H, 
Phenyl),  6.55(s, 1H, Imidazole-CH), 6.72(s, 1H, 
CH), 2.3(1H,NH), 2.1(s,1H,NH); 13C 
NMR(DMSO-d6, 300MHz); 1810.7 (C=S),  136.6, 
132.3, 128.6, 128.3 (Ph-Cl), 128.0 (Imidazole 
ring CH=CH), 138.1 (HC=N), 76.8(CH). EI-MS, 
m/z (Relative intensity %): [281.76+, 37 %]. 
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2-((4-Hydroxyphenyl) (1H-imidazol-1-yl) 
methyl) hydrazinecarbothioamide (1c)  
 
IR (KBr,cm-1): 3290.21(NH2), 2914.16(NH), 
1435.83(C=S), 809.97(Ar-H), 458(CH); 1HNMR 
(DMSO-d6, 300MHz):  9.52(s, 2H, NH2),  9.47 
(1H, s, C–OH),  9.43 (s, 1H, 9.43), 7.80 (s, 1H, 
CH), 6.63 – 7.08 (tt, 4H, Phenyl),  6.73 (s, 1H, 
Imidazole-CH), 6.78 (s, 1H, CH), 2.4 (1H,NH), 
2.1 (s,1H,NH); 13C NMR(DMSO-d6, 300MHz); 
1821.4 (C=S), 115.7, 128.3, 131.2 (Ph - OH), 
127.9 (Imidazole ring CH=CH), 138.2 (HC=N), 
74.2(CH). EI-MS, m/z (Relative intensity %): 
[263.31+, 26 %]. 
 
2-((1H-Imidazol-1-yl) (4-nitrophenyl) methyl) 
hydrazinecarbothioamide (1d)   
 
IR(KBr,cm-1): 3294.29 (NH2), 2915.15 (NH), 
1435.88 (C=S), 814.90 (Ar-H), 1536 (C–NO2), 
458.92 (CH); 1H NMR (DMSO-d6, 300MHz): 9.51 
(s, 2H, NH2), 7.80 (s, 1H, CH), 7.22-7.64 (m, 5H, 
Phenyl),  6.77 (s, 1H, Imidazole-CH), 6.84 (s, 1H, 
CH), 2.4 (s, 1H, NH), 2.1 (s, 1H, NH); 13C NMR 
(DMSO-d6, 300MHz); 181.8 (C=S), 155.2, 131.6, 
128.3, 127.9 (Ph-NO2),, 128.2 (Imidazole ring 
CH=CH), 136.3 (HC=N), 74.8 (CH); EI-MS, m/z 
(Relative intensity %): [292.31+ , 36 %]. 
 
2-((1H-imidazol-1-yl) (4-methoxyphenyl) 
methyl) hydrazinecarbothioamide (1e)  
 
IR (KBr, cm-1): 3288.20 (NH2),  2912.14 (NH), 
1432.80 (C=S), 812.95 (Ar-H), 458.67 (CH); 1H 
NMR (DMSO-d6, 300MHz): 9.51 (s, 2H, NH2), 
7.88 (s, 1H, CH),  6.88 – 7.10 (tt, 4H, Ph – 
OCH3),  6.68 (s, 1H, Imidazole-CH), 6.80 (s, 1H, 
CH), 3.84 (s, 3H, –OCH3), 2.1 (s, 1H, NH), 2.0 
(s, 1H, NH); 13C NMR (DMSO-d6, 300MHz): 
1818.6 (C=S), 158.6, 130.9, 114.0, 126.0(Ph -
OH), 128.1 (Imidazole ring CH=CH), 55.7 (Ph–
OCH3), 134.2 (HC=N), 74. 8(CH); EI-MS, m/z 
(Relative intensity %): [277.34+ , 28 %]. 
 
2-((4-(dimethylamino) phenyl) (1H-imidazol-1-
yl) methyl) hydrazinecarbothioamide (1f)  
 
IR (KBr, cm-1): 3282.16 (NH2), 2912.12 (NH), 
1438.82 (C=S), 808.92 (Ar-H), 460 (CH); 1H 
NMR (DMSO-d6, 300MHz): 9.53 (s, 2H, NH2), 
7.83 (s, 1H, CH), 7.02 – 6.64 (tt, 4H, Ph – 
N(CH3)2),  6.70 (s, 1H, Imidazole-CH), 3.12 (s, 
6H,  –N(CH3)2), 6.84 (s, 1H, CH), 2.2(1H,NH), 
2.0 (s, 1H, NH); 13C NMR (DMSO-d6, 300Mhz): 
180.6 (C=S), 148.3, 128.1, 127.2, 112.8, 40.2 
(Ph – N (CH3)2), 126.2 (Imidazole ring CH=CH), 
136.8 (HC=N), 40.8 (–N(CH3)2), 74.0 (CH); EI-
MS, m/z (Relative intensity %): [290.38+ , 37 %].  
 
2-((1H-Imidazol-1-yl) (p-tolyl) methyl) 
hydrazinecarbothioamide (1g)  
 
IR(KBr,cm-1): 3280.22 (NH2), 2914.13 (NH), 
1430.82 (C=S), 814.96 (Ar-H), 454.89(CH); 1H 
NMR (DMSO-d6, 300MHz): 9.50 (s, 2H, NH2), 
7.82 (s, 1H, CH), 7.11 - 7.14 (tt, 4H, Ph – 
CH3),  6.56 (s, 1H, Imidazole-CH), 6.82 (s, 1H, 
CH), 2.42 (s, 1H, NH),  2.33 (s, 3H, -CH3), 2.21 
(s, 1H, NH); 13C NMR (DMSO-d6, 300MHz); 
184.5 (C=S), 135.9, 135.4, 128.5, 126.8 (Ph –
CH3), 128.5 (Imidazole ring CH=CH), 137.2 
(HC=N), 74.6 (CH); EI-MS, m/z (Relative 
intensity %): [261.34+ , 22 %]. 
 
2-[1H-Imidazol-1-yl (phenyl) methyl] 
hydrazinecarboxamide (2a) 
 
IR(KBr,cm-1) : 3287.20 (NH2), 2932.97 (NH), 
1623.21 (C=O), 819.78 (Ar-H), 456.98 (CH) 1H 
NMR (DMSO d6,300 MHz): 9.50 (s, 2H, NH2), 
7.86 (s, 1H, CH), 7.26-7.65 (m, 5H, Phenyl), 6.89 
(s, 1H, Imidazole-CH), 6.76 (s, 1H, CH), 2.21 
(1H, NH), 2.09 (s, 1H, NH) 13C NMR (DMSOd6, 
300MHz); 157.9 (C=O), 126.1, 126.8, 128.5, 
138.9 (Phenyl), 128.1 (Imidazole ring CH=CH), 
137.1 (HC=N), 75.9 (CH).  EI-MS, m/z (Relative 
intensity %): [231.28 +, 51 %]. 
 
2-((4-Chlorophenyl) (1H-imidazol-1-yl) methyl) 
hydrazinecarboxamide (2b)  
 
IR (KBr, cm-1) : 3281.18 (NH2), 2930.92 (NH), 
1621.18 (C=O), 837(C-Cl), 818.71 (Ar-H), 455.91 
(CH); 1H NMR (DMSO d6, 300 MHz): 9.52 (s, 2H, 
NH2), 7.82 (s, 1H, CH), 7.36 - 7.16 (tt, 4H, 
Phenyl), 6.86 (s, 1H, Imidazole-CH), 6.74 (s, 1H, 
CH), 2.20 (1H, NH), 2.12 (s, 1H, NH); 13C NMR 
(DMSOd6, 300MHz); 157.2 (C=O), 136.6, 132.3, 
128.6, 128.3 (Ph-Cl) 128.4 (Imidazole ring 
CH=CH), 137.6 (HC=N), 76.5 (CH);  EI-MS, m/z 
(Relative intensity %): [265.70+, 38 %]. 
 
2-((4-Hydroxyphenyl) (1H-imidazol-1-yl) 
methyl) hydrazinecarboxamide (2c)  
 
IR (KBr,cm-1) : 3280.24 (NH2), 2930.94 (NH), 
1624.23 (C=O), 816.76 (Ar-H), 1472 (C–OH), 
457.91(CH); 1H NMR (DMSO d6, 300 MHz): 9.46 
(s, 2H, NH2), 9.41 (1H, s, OH), 7.84 (s, 1H, CH), 
6.63 – 7.08 (tt, 4H, Phenyl),  6.86 (s, 1H, 
Imidazole-CH), 6.74 (s, 1H, CH), 2.19 (1H, NH), 
2.12 (s, 1H, NH); 13C NMR (DMSOd6, 300MHz); 
155.6 (C=O), 125.2, 126.6, 128.2, 138.4 
(Phenyl), 128.4 (Imidazole ring CH=CH), 136.5 
(HC=N), 115.7, 128.3, 131.2 (Ph - OH), 75.2 
(CH);  EI-MS, m/z (Relative intensity %): 
[247.25+, 33 %]. 
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2-((1H-Imidazol-1-yl) (4-nitrophenyl) methyl) 
hydrazinecarboxamide (2d)  
 
IR(KBr,cm-1) : 3278.10 (NH2), 2930.91 (NH), 
1622.18 (C=O), 813.18 (Ar-H), 1530 (C–NO2), 
455.91(CH); 1H NMR (DMSO d6,300 MHz): 9.46 
(s, 2H, NH2), 7.84 (s, 1H, CH), 7.26-7.65(m, 5H, 
Phenyl), 6.88 (s, 1H, Imidazole-CH), 6.74 (s, 1H, 
CH), 2.18 (1H, NH), 2.12 (s, 1H, NH); 13C NMR 
(DMSOd6, 300MHz); 156.8 (C=O), 155.2, 131.6, 
128.3, 127.9 (Ph-NO2),, 128.6 (Imidazole ring 
CH=CH), 136.4 (HC=N),  75.2 (CH).  EI-MS, m/z 
(Relative intensity %): [276.25+, 30 %].     
 
2-((1H-Imidazol-1-yl) (4-methoxyphenyl) 
methyl) hydrazinecarboxamide (2e)  
 
IR (KBr,cm-1) : 3276.10 (NH2), 2936.87 (NH), 
1628.22 (C=O), 816.72 (Ar-H), 456.94 (CH) 1H 
NMR (DMSO-d6, 300 MHz): 9.54 (s, 2H, NH2), 
7.85 (s, 1H, CH), (tt, 4H, Ph – OCH3),  6.86 (s, 
1H, Imidazole-CH), 6.74 (s, 1H, CH), 3.81 (3H, s, 
–OCH3), 2.18 (1H, NH), 2.10 (s, 1H, NH); 13C 
NMR (DMSO-d6, 300MHz); 158.6 (C=O), 158.6, 
130.9, 114.0, 126.0 (Ph -OH),  128.2 (Imidazole 
ring CH=CH), 137.3 (HC=N), 55.9 (–OCH3); 74.8 
(CH);  EI-MS, m/z (Relative intensity %): 
[261.28+, 54 %]. 
 
2-((4-(Dimethylamino) phenyl) (1H-imidazol-1-
yl) methyl) hydrazinecarboxamide (2f)  
 
IR(KBr,cm-1) : 3281.21 (NH2), 2929.91 (NH), 
1627.27 (C=O), 817.71 (Ar-H), 453.96 (CH); 1H 
NMR (DMSO-d6,300 MHz): 9.47 (s, 2H, NH2), 
7.81(s, 1H, CH), (tt, 4H, Ph – N(CH3)2),  6.82 (s, 
1H, Imidazole-CH), 6.72 (s, 1H, CH), 3.06 (1H, s, 
–N (CH3)2), 2.27 (1H, NH), 2.12 (s, 1H, NH); 13C 
NMR (DMSO-d6, 300MHz); 156.2 (C=O), 148.3, 
128.1, 127.2, 112.8, 40.2 (Ph – N(CH3)2), 
128.6(Imidazole ring CH=CH), 136.5(HC=N), 
40.8 (N(CH3)2), 76.2 (CH).  EI-MS, m/z (Relative 
intensity %): [274.32+, 23 %]. 
 
2-((1H-Imidazol-1-yl)(p-tolyl) methyl) 
hydrazinecarboxamide (2g)  
 
IR (KBr,cm-1) : 3266.21(NH2), 2930.70(NH), 
1622.19(C=O), 818.18(Ar-H), 455.18(CH); 1H 
NMR (DMSO-d6, 300 MHz): 9.52(s, 2H, NH2), 
7.81(s, 1H, CH), 7.26-7.65(tt, 4H, Phenyl), 6.87 
(s, 1H, Imidazole-CH), 6.75 (s, 1H, CH), 2.34 (s, 
3H, CH3), 2.26 (1H, NH), 2.10 (s, 1H, NH); 13C 
NMR (DMSO-d6, 300MHz); 155.6 (C=O), 135.9, 
135.4, 128.5, 126.8 (Ph –CH3), 128.8 (Imidazole 
ring CH=CH), 136.9(HC=N), 75.1 (CH).  EI-MS, 




Antibacterial activity  
 
Compounds 1a-g and 2a-2g were evaluated for 
in vitro antibacterial activity against 
Staphylococcus aureus, Escherichia coli, 
Enterococcus. faecalis. Pseudomonas 
aeruginosa and Klebsiella pneumoniae using 
conventional agar dilution procedures. 
Ciprofloxacin was used as a positive control.  
Inhibition zones were measured and compared 
against those of controls. The bacterial zones of 
inhibition are given in Table 2. 
 
Compared with ciprofloxacin, compound 1b was 
highly active against S. aureus, and 1g exhibited 
an equivalent activity (0.5 μg/mL) against E. 
faecalis and greater activity (0.25 μg/mL) against 
P. aeruginosa. Compound 2e was highly active 
against K. pneumonia and 2f showed equivalent 
activities (0.5 μg/mL) against E. coli and E. 
feacalis. Compound 2g was highly active (0.5 
μg/mL) against P. aeruginosa. The MIC values 




Compounds 1a-g and 2a-g were evaluated in 
terms of their in vitro antifungal activity against 
Aspergillus niger, Candida albicans, Aspergillus 
fumigatus, Cryptococcus neoformans 
(recultured), and Microsporum audouinii using an 
agar diffusion method. The fungal activity of each 
compound was compared with that of 
clotrimazole as positive control. The fungal zones 
of inhibition are given in Table 2.  Compounds 2d 
and 2g (0.25 μg/mL) were highly active against 
C. albicans. Compound 2d was equipotent active 
(1 μg/mL) against M. audouinii compared with 
clotrimazole (MIC, 2 μg/ml). 
 
Larvicidal activity  
 
The larvicidal activity of the test compounds is 
listed in Table 4.  Larvicidal activity was 
determined for compounds 1a-g and 2a-g by 
exposing second instar larvae for 24 h at room 
temperature. With the exception of 1g, the 
compounds exhibited moderate larvicidal activity 
against mosquito. Compounds 1a, 1b, 1d, 1f, 2a, 
2b, 2c, 2d, 2f and 2g) yielded 100 % mortality at 
40 µg/mL. Compound 1g was particularly toxic 




Compounds 1a-g and 2a-g were alao evaluated 
in terms of their in vitro nematicidal activity 
against Meloidogyne javanica at various aqueous 
concentrations. Compound 1g was the most 
effective nematicide as evidenced by its LD50 of 
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8.9 μg/mL. Compounds (1d, 1e, 1f, 1g, 2d and 
2e) were more potent then compounds (1a, 1b, 
2a, 2b, 2c, 2f, and 2g), which exhibited 100 % 
mortality at 30 µg/mL. LD50 values are reported 
in Table 5. 
 
 




R M.W M.F M.P(°C) Elemental analysis 
(Calculated  & found) 
C H N S 








































1f -N(CH3)2 290.38 C13H18N6S 164    53.77 





































































Antibacterial screnning   
 
Antifungal screnning  
S. a 
 




A.n C.a A.f C.n M.a 
1a 12 - - 12 -  7 - - - 14 
1b 28 8 10 10 12  16 24 15 7 13 
1c 16 - - 16 19  10 6 - - 8 
1d 20 - 12 18 8  - 7 - 16 6 
1e 18 12 - 12 10  17 26 - 7 8 
1f 15 - 14 14 -  - 15 - 9 - 
1g - 24 25 26 12  9 17 - 16 - 
2ª 10 12 - - 10  - 7 - 9 - 
2b 5 - - 10 12  15 10 8 10 8 
2c - - 12 12 8  - - - - 16 
2d 12 10 10 15 -  10 16 14 - 20 
2e - 16 - 28 -  - 12 6 8 - 
2f 22 24 25 - 10  - 16 - 23 - 
2g 12 - 10 26 19  18 28 11 20 10 
Ciprofloxacin 26 28 22 15 19  - - - - - 
Clotrimazole - - - - -  22 26 16 30 18 
Clotrimazole was used as a standard; zone of inhibition was measured in mm  
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      Table 3: Minimum inhibitory concentrations (MIC, µg/mL) of compounds 1a-g and 2a-g 
 
 Minimum Inhibitory Concentration (MIC, µg/mL)a 











A.n C. a A.f C. n M. a 
1b 0.25 - - 32 - 32  4  64  - >100 
1c 16 - - 16 4 >100 >100 - - >100 
1d 2 - 64 1 >100 - >100 -  64 >100 
1g - 1 0.5 0.25 64    32 1 - >100 >100 
2d 64 64 64 16 - 64  0.25  64 - 1 
2e - 4 -  0.5 -  32 >100 >100 - 
2f 2 0.5 0.5 - 64 -  16 - 2 - 
2g 64 - 64 0.5 2 4   0.5 >100 2 32 
Ciproflaxacin 0.5 0.5 0.5 4 2 - - - - - 
Clotrimazole - - - - - 2       1 8  0.5  2 
         -, Not determined 
 








10 20 30 40 
1ª 25 ± 4.8 51 ± 3.1 79 ± 8.2 100 ± 0.0 19.5 
1b 22 ± 3.7 75 ± 4.8 90 ± 2.5 100 ± 0.0 16.2 
           1c 29 ± 4.1 54 ± 40 100 ± 0.0 - 16.9 
1d 18 ± 1.2 51 ± 1.2 76 ± 4.2 100 ± 0.0 20.8 
1e 45 ± 2.9 86 ± 2.5 100 ± 0.0 - 10.1 
1f 27 ± 4.8 64 ± 4.0 82 ± 4.2 100 ± 0.0 17.2 
           1g 52 ± 4.1 73 ± 4.2 100 ± 0.0 - 9.5 
 2a 20 ± 2.2 59 ± 7.3 74 ± 3.8 100 ± 0.0 19.8 
 2b 24 ± 2.1 40 ± 3.8 82 ± 5.7 100 ± 0.0 19.1 
 2c 20 ± 3.2 46 ± 4.8 60 ± 3.9 100 ± 0.0 22.4 
 2d 10 ± 3.2 32 ± 2.5 66 ± 3.8 100 ± 0.0 24.3 
 2e 28 ± 3.1 62 ± 4.0 100 ± 0.0 - 16.2 
 2f 22 ± 3.7 63 ± 3.5 71± 1.7 100 ± 0.0 19.2 
 2g 30 ± 4.8 58 ± 3.8 92 ± 4.2 100 ± 0.0 16.8 
         Values are mean ± SD (n = 3) 
 








(μg /mL) 10 20 30 40 
1a 20 ± 3.8 49 ± 3.7  87 ± 3.2 100 ± 0.0 20.6 
1b 40 ± 4.1 51 ± 2.3  80 ± 1.9 100 ± 0.0 16.5 
              1c 39 ± 4.1 76 ± 2.3 100 ± 0.0 - 12.8 
1d 43 ± 4.8 71 ± 5.7 100 ± 0.0 - 12.5 
1e 42 ± 4.0 61 ± 1.8 100 ± 0.0 - 13.9 
1f 42 ± 4.1 53 ± 4.1 100 ± 0.0 - 14.8 
              1g 54± 4.8 72 ± 2.3 100 ± 0.0 -  8.9 
2a 18 ± 2.1 36 ± 4.4  60 ± 2.0 100 ± 0.0 23.7 
2b 30 ± 3.2 56 ± 3.2  72 ± 3.9 100 ± 0.0 18.5 
2c 38 ± 1.9 40 ± 3.8   60 ± 2.0 100 ± 0.0 20.3 
2d 23 ± 5.0 52 ± 4.1 100 ± 0.0 - 17.8 
2e 42 ± 4.1 66 ± 2.2 100 ± 0.0 - 13.3 
2f 28 ± 3.0 47 ± 2.8  62 ± 2.0 100 ± 0.0 20.9 
2g 16 ± 1.2 45 ± 4.1  67 ± 3.9 100 ± 0.0 22.4 
Values are the means of three replicates ± SD 
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We synthesised and characterised 14 new 
Mannich base imidazole derivatives (1a-g) and 
(2a-g) as outlined in Scheme 1. The physical 
data of these compounds are given in Table 1. 
 
The Mannich base condensation reaction 
proceeds via an attack by benzaldehyde at a 
secondary amine.  During this reaction, one mole 
of water was eliminated and the resulting 
thiazolidine-4-one products were purified by 
column chromatography using an eluent of 
hexane: chloroform (1:4)  
 
The chemical structure of each new compound 
was confirmed by IR, ¹H NMR, 13C NMR, mass, 
and elemental analysis. The IR spectrum of 
compound 1a showed absorption bands at 
3292.26, 2916.17, 1436.87 and 460.03 cm-1  
corresponding to NH2, NH, C=S and CH groups. 
The ¹H NMR spectrum of the compounds 1a 
showed broad signals at 9.53, 7.83 and 2.20 
ppm corresponding to NH2, CH and NH protons 
respectively. The 13C NMR spectra of 1a 
contained important peaks at 182.7 and 75.3 
ppm, corresponding to C=S and CH carbon 
atoms, respectively.  The mass spectrum of 1a 
contained a molecular ion peak m/z 247.28, 
thereby confirming its molecular mass. Similar 
spectral data and corresponding molecular 
masses were obtained for compounds (1b-1g). 
 
Similarly, the IR spectrum of compound 2a 
showed absorption bands at 3287.20, 2932.97, 
1623.21 and 456.98 cm-1  corresponding to NH2, 
NH, C=O and CH groups respectively. The ¹H 
NMR spectrum of 2a showed broad signals at 
9.50, 7.86 and 2.21 ppm, corresponding to NH2, 
CH and NH protons respectively. The 13C NMR 
spectrum of compound 2a showed important 
peaks  at 157.9 and 75.9 ppm, corresponded to 
C=O and CH carbon atoms respectively.  The 
mass spectrum of 2a contained a molecular ion 
peak m/z 231.28, which is consistent with its 
molecular mass. Similar spectral data and 
corresponding molecular masses were obtained 
for compounds (2b-2g). 
 
The synthesized imidazole derivatives were 
evaluated in terms of their antimicrobial, larvicidal 
and, nematicidal activities.  Consistent with their 
expected structure - activity relationship, 
compounds 1a-1g and 2a-2g were biologically 
active. The presence of imidazole nucleus and 
the para substitution of the phenyl ring contribute 
to the observed activities. 
 
The chemical structure in Figure 1 show that the 
4-substituted phenyl ring acts as a lipophilic 
domain. The C=S group in thiosemicarbazone 
and the C=O group in semicarbazone form 
hydrogen bonds with the NH groups in 
thiosemicarbazone and semicarbazone act as 
hydrogen bonding domain. Therefore, the 
imidazole ring is an essential pharmacophore 
that determine biological activity.  
 
Compound 1b, which contains a 4-substituted 
chlorine atom showed significant antibacterial 
activity against S. aureus (MIC, 0.25 μg/mL) 
relative to that of the positive control 
ciproflaxiacin (MIC: 0.5 μg/mL). 
 
Compound 1g, with a 4-substituted methyl group, 
exhibited a remarkable activity against P. 
aeruginosa (MIC, 0.25 μg/mL) compared with 
that of ciprofloxacin (MIC, 4 μg/mL). 
 
Compound 2d containing a 4-NO2 group 
exhibited an excellent antifungal activity (MIC, 
0.25 μg/mL) against C. albicans relative to the 
activities of the synthesized compounds and the 










       
          Compound 1b 
Staphylococcus aureus 
MIC:0.25 µg/mL 











 Pseudomonas aeruginosa :MIC:0.25 μg/mL
Nematicidal activity LD50 =8.9 μg /mL 









          
        Compound 2d 
      Candida albicans, 
       MIC:0.25 µg/mL 
 
Figure 1: Structure activity relationships of synthesised imiazole derivatives 
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Compound 1g, which contains a 4-CH3-phenyl 
group with thiosemicarbazone and imidazole 
moieties, was a potent larvicide (LD50: 9.5 
μg/mL) and nematicide (LD50, 8.9 μg/mL) while 
compound 2g (4-CH3-phenyl with semicarbazide 
and imidazole moieties) showed no significant  
nematicidal (LD50, 22.9 μg/mL) or  larvicidal 
(LD50, 16.8 μg /mL) activities.   
 
Compound 1e, which also contains a 4-CH3O-
phenyl with thiosemicarbazone and imidazole 
moieties, was also a potent larvicide (LD50, 10.1 
μg/mL) and nematicide (LD50, 13.9 μg/mL), while 
compound 2e was less active against mosquito 
larvae (LD50, 16.2 μg /mL) and highly active 
against nematodes (LD50, 13.9 μg/mL). However, 





A new series of imidazole derivatives has been 
synthesized. Some of them possess strong 
larvicidal, nematicidal, antibacterial and 
antifungal activities, and thus are capable of 
serving as potential lead molecules for the 
development of clinically useful antimicrobial, 
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